News from Tuesday, February 4, 2025
Articles
Olaparib Leads PARP Inhibitors in Boosting OS for Platinum-Sensitive Recurrent Ovarian Cancer
(2/3, Brooke McCormick, The American Journal of Managed Care) reports “While all poly ADP-ribose polymerase (PARP) inhibitors have demonstrated improvements in progression-free survival (PFS), only olaparib prolonged overall survival (OS), according to a recently published review, indicating it may be the preferred option for patients with platinum-sensitive recurrent ovarian cancer (PSROC).” Full
U.S. Taxpayers Should Stop Funding Clinical Trials of Industry-Owned Drugs
(2/4, Mark J. Ratain, STAT) comments “...[A] new approach dedicated to long-neglected taxpayer and government payer concerns — quality of life, financial sustainability and efficiency of cancer care, and comparative effectiveness — is needed. Such a strategy would focus government’s limited clinical trials effort on studies where the expected value of the information generated is positive for taxpayers but unambiguously negative for industry.” Full
Press Releases
Guideline on Migraine Prevention Says No Clinically Important Advantages for Newer, Expensive Medications
(2/3, American College of Physicians Press Release) “...Because of the lack of differences in clinical net benefit between virtually all treatments, the CGC used economic evidence and patients' values and preferences data as primary factors in prioritizing different migraine prevention treatments. The median annual costs of recommended initial oral treatments varied substantially.” Full
OpenNotes Joins PCORI-Funded Study to Advance Equity in Health Research
(2/4, OpenNotes Press Release) “OpenNotes is proud to announce its participation in the Characterizing Engagement and Equity in Research (CHEER) study, an initiative led by researchers at the University of Colorado. Funded by a $2.1 million award from the Patient-Centered Outcomes Research Institute (PCORI), the CHEER study aims to improve methods of engaging diverse and historically underrepresented communities in health research.” Full
Kate Tarpey Appointed to Serve in New Position for the Organization
(2/4, ISPOR Press Release) “ISPOR—The Professional Society for Health Economics and Outcomes Research announced today that Kate Tarpey has been appointed as chief financial officer for the Society. This is a new position at ISPOR and speaks to the growth of both the Society and the increasing role of health economics and outcomes research (HEOR) in healthcare.” Full
Journals
A Comprehensive Comparison of PARP Inhibitors as Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Network Meta-Analysis
Shiya Ji, et al.
January 30, 2025, Journal of Ovarian Research
Comparative Effectiveness of Pharmacologic Treatments for the Prevention of Episodic Migraine Headache: A Systematic Review and Network Meta-analysis for the American College of Physicians
Johanna A A Damen, et al.
February 4, 2025, Annals of Internal Medicine
Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians
Amir Qaseem, MD, PhD, MHA, et al.
February 4, 2025, Annals of Internal Medicine